- Report
- January 2026
- 197 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 190 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- March 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- January 2026
- 110 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- May 2025
- 287 Pages
Global
From €3897EUR$4,450USD£3,383GBP
- Report
- November 2025
- 160 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- April 2025
- 200 Pages
United States
From €2181EUR$2,490USD£1,893GBP
- Report
- August 2025
- 122 Pages
United States
From €3502EUR$3,999USD£3,040GBP
- Report
- June 2025
- 119 Pages
United States
From €3502EUR$3,999USD£3,040GBP
- Report
- January 2024
- 126 Pages
Global
From €4073EUR$4,650USD£3,535GBP
- Report
- January 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Report
- August 2025
- 118 Pages
Japan
From €3502EUR$3,999USD£3,040GBP
- Report
- February 2025
- 137 Pages
Canada
From €3502EUR$3,999USD£3,040GBP
- Report
- June 2023
- 233 Pages
Global
From €3153EUR$3,600USD£2,737GBP

Authorized generics are generic drugs that are produced and marketed by the same company that manufactures the brand-name version of the drug. This allows the company to maintain control over the production and distribution of the drug, while still providing a lower-cost alternative to the brand-name version. Authorized generics are typically priced lower than the brand-name version, but higher than other generic versions of the same drug.
The authorized generics market has grown in recent years as more companies have sought to capitalize on the cost savings associated with generic drugs. This has allowed companies to increase their market share and expand their product offerings.
Some of the major players in the authorized generics market include Teva Pharmaceuticals, Mylan, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more